Q3 FY26 Results: PAT up 209% YoY on JCE share of profit

Revenue DeclinePat Growth 25pctResults View source PDF Explain this filing

BROOKS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+11.1%Reaction day

₹61.45

prior close

₹62.99

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+2.6%+8.5% vs market

On the reaction day the stock moved 8.5 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+2.4

15m

+1.6

30m

+1.6

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

+11.1+2.6+8.5

Next day

+21.6+3.6+18.0

+25.8+3.1+22.7

+24.5+2.6+21.9

+24.3+1.1+23.3

+20.6+0.3+20.3

+24.1+1.6+22.5

15d

+2.4-3.9+6.3

-5.4-8.1+2.7

+17.1-3.1+20.1

-22.8+9.2-32.0

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Brooks Labs reported Q3 FY26 standalone revenue of Rs 1,656.63L (down 19% from Rs 2,051.51L YoY), with PAT at Rs 30.28L vs Rs 93.65L. For 9M FY26, revenue grew 10.6% to Rs 6,552.89L and PAT jumped 209% to Rs 519.07L. Consolidated 9M PAT was Rs 2,306.05L (vs loss of Rs 850.90L) driven by JCE Brooks Steriscience's Rs 1,786.98L share of profit. Object Clause alteration not approved by RoC.

Likely market impact

Strong consolidated turnaround driven by JCE Steriscience profits. Standalone operations remain weak with declining quarterly revenue and margins.